Amneal wins FDA supplement approval for mycophenolate mofetil oral suspension REMS update
FDA approved a REMS-related supplement for Amneal's mycophenolate mofetil for suspension, 200mg/mL, under ANDA214871.
This week's sole item is a regulatory update for Amneal's generic immunosuppressant product.
- Amneal's mycophenolate mofetil for oral suspension, 200mg/ml, received approval on a REMS-class supplement (submission number 13) under ANDA214871, with a submission status date of 2026-07-29.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.